A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA 2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade

January 16, 2019
https://clinicaltrials.gov/ct2/results?id=NCT03739931
Solid Tumors
Principal Investigator: Ding Wang, MD
Solid Tumor, Breast, Head, Neck, Lymphoma, Melanoma
Accepting Participants